Investing.com -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA)公布的第二季度收入超过分析师预期,但由于该罕见疾病专注公司的盈利大幅低于预期,股价下跌了3%。 该公司报告第二季度调整后每股收益为-$0.06,远低于分析师一致预期的$2.19。收入达到2590万美元,超过了分析师一致预期的2249万美元,并且较去年同期的440万美元有显著增长。 ...
Source LinkInvesting.com -- Zevra Therapeutics, Inc. (NASDAQ:ZVRA)公布的第二季度收入超过分析师预期,但由于该罕见疾病专注公司的盈利大幅低于预期,股价下跌了3%。 该公司报告第二季度调整后每股收益为-$0.06,远低于分析师一致预期的$2.19。收入达到2590万美元,超过了分析师一致预期的2249万美元,并且较去年同期的440万美元有显著增长。 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.